| Name | Title | Contact Details |
|---|
Why American Addiction Centers? We take a big picture approach to addiction recovery treatment – addressing the individual`s whole lifestyle in relation to substance use, alcohol and binge eating addiction and partnering with the family throughout the treatment process whenever possible. With our research-based programs, our inpatient treatment centers don`t just focus on the problem; we strengthen the individual and focus on the future. Whether it`s the initial clinical assessments, medically supervised detox, residential rehabilitation or aftercare, our team is present for and committed to each step of the recovery process for every individual. American Addiction Centers is an equal opportunity and drug free employer. All decisions regarding recruiting and hiring will be made without unlawful discrimination on the basis of race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, or age.
Vasade Biosciences is a Long Beach Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
US Re Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Houston, TX. To find more information about US Re Corporation, please visit www.usre.com
Mada is a manufacturer of several hundred Medical, Dental, Podiatric and Veterinary products catering to the Home Healthcare and Institutional markets. Mada was incorporated in 1969, with Production and Corporate Offices located in Carlstadt, New Jersey
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.